Marta Gil-Martín

5.5k total citations · 2 hit papers
108 papers, 2.0k citations indexed

About

Marta Gil-Martín is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Marta Gil-Martín has authored 108 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 18 papers in Molecular Biology. Recurrent topics in Marta Gil-Martín's work include Cancer Immunotherapy and Biomarkers (28 papers), Advanced Breast Cancer Therapies (22 papers) and Cancer Treatment and Pharmacology (20 papers). Marta Gil-Martín is often cited by papers focused on Cancer Immunotherapy and Biomarkers (28 papers), Advanced Breast Cancer Therapies (22 papers) and Cancer Treatment and Pharmacology (20 papers). Marta Gil-Martín collaborates with scholars based in Spain, United States and Germany. Marta Gil-Martín's co-authors include Víctor Moreno, Cornelia Quadt, Valentina Boni, Douglas Bootle, David Demanse, Martin Schüler, Dejan Juric, José Baselga, Howard A. Burris and Ruth Seggewiss‐Bernhardt and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Marta Gil-Martín

102 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

2019 400 citations Víctor Moreno, Marta Gil-Martín et al. profile →
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Marta Gil-Martín

Since Specialization

Citations

This map shows the geographic impact of Marta Gil-Martín's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Gil-Martín with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Gil-Martín more than expected).

Fields of papers citing papers by Marta Gil-Martín

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Gil-Martín. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Gil-Martín. The network helps show where Marta Gil-Martín may publish in the future.

Co-authorship network of co-authors of Marta Gil-Martín

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Gil-Martín. A scholar is included among the top collaborators of Marta Gil-Martín based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Gil-Martín. Marta Gil-Martín is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SEOM-GEICO clinical guidelines on endometrial cancer (2025) 2025 ·Clinical & Translational Oncology ·(unknown), (unknown), M.P. Barretina Ginesta, (unknown), (unknown), (unknown), (unknown), Ainhoa Madariaga, (unknown), Marta Gil-Martín	0
2	401P Vibostolimab coformulated with pembrolizumab (vibo/pembro) + chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study 2024 ·Annals of Oncology ·(unknown), (unknown), (unknown), Sercan Aksoy, Marta Gil-Martín, Christoph Roderburg, (unknown), (unknown), (unknown), (unknown), S-B. Kim, (unknown), Sebastian Ochsenreither, Mehmet Alı Nahıt Şendur, (unknown), (unknown), Qiaofei Liu, (unknown), Jane Healy, Mariusz Kwiatkowski	1
3	A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results. 2024 ·Journal of Clinical Oncology ·Nehal J. Lakhani, Omid Hamid, Irene Braña, (unknown), Pablo Gajate, (unknown), Paul Swiecicki, Maria J. de Miguel, Marta Gil-Martín, Víctor Moreno, (unknown), (unknown), Dylan Sun, Dimple Modi, Wenjun Zheng, Vladimir Janković, Mark Salvati, Matthew G. Fury, (unknown)	2
4	Abstract CT114: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC) 2024 ·Cancer Research ·Byoung Chul Cho, John Hilton, Cristina P. Rodriguez, Marcelo Bonomi, Lillian L. Siu, Marta Gil-Martín, (unknown), (unknown), (unknown), Douglas C. Wilson, (unknown), Rafał Dziadziuszko	1
5	SEOM-GEICO Clinical Guidelines on cervical cancer (2023) 2024 ·Clinical & Translational Oncology ·Luís Manso, (unknown), Ignacio A. Romero, Luisa Sánchez‐Lorenzo, (unknown), Purificación Estévez-García, (unknown), Yolanda García García, Marta Gil-Martín, María Quindós	7
6	Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial 2024 ·Gynecologic Oncology ·Mansoor R. Mirza, Line Bjørge, Frederik Marmé, René dePont Christensen, Marta Gil-Martín, Annika Auranen, Beyhan Ataseven, María Jesús Rubio, (unknown), A.A. Luczak, Ingo B. Runnebaum, Andrés Redondo, Kristina Lindemann, Fabian Trillsch, M.P. Barretina Ginesta, Henrik Roed, J.E. Kurtz, (unknown), Gitte‐Bettina Nyvang, (unknown)	3
7	761P A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular classification 2023 ·Annals of Oncology ·J.M. Piulats Rodriguez, (unknown), Jesús Alarcón, Sónia Gatius, (unknown), Marta Gil-Martín, (unknown), Marı́a Santacana, (unknown), (unknown), (unknown), Xavier Matías‐Guiu, Margarita Romeo, (unknown), (unknown)	1
8	Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study) 2023 ·Clinical Cancer Research ·Beatriz Tavira, (unknown), Luís Manso, Ana Santaballa, Marta Gil-Martín, Yolanda García García, Margarita Romeo, María Iglesias, (unknown), Maria-Pilar Barretina-Ginesta, Aránzazu Manzano, Lydia Gaba, María Jesús Rubio, Carlos E. de Andrea, Antonio González-Martı́n	6
9	Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery 2023 ·International Journal of Molecular Sciences ·Andrea Plaja, (unknown), María Ochoa-de-Olza, Marc Cucurull, (unknown), Beatriz Pardo, (unknown), Marta Gil-Martín, Josep M. Piulats, (unknown), (unknown), Anna Carbó, Maria-Pilar Barretina-Ginesta, Sergio Martínez‐Román, (unknown), (unknown), Anna Esteve, Margarita Romeo	3
10	583P Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model 2022 ·Annals of Oncology ·José Alejandro Pérez Fidalgo, (unknown), Victoria Heredia-Soto, Margarita Romeo, Marta Mendiola, (unknown), Adrià Bernat‐Peguera, (unknown), Andrés Redondo, Marta Gil-Martín, (unknown), (unknown), Octavio Burgués, Andrés Cervantes, Barbara Merlo	0
11	Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort 2021 ·Lung Cancer ·Víctor Moreno, Pilar Garrido, Kyriakos P. Papadopoulos, Maria J. de Miguel, Marta Gil-Martín, Raid Aljumaily, Lee S. Rosen, Petra Rietschel, Kosalai Kal Mohan, Suk‐Young Yoo, Elizabeth Stankevich, Israel Lowy, Matthew G. Fury	11
12	LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer 2021 ·Annals of Oncology ·Zev A. Wainberg, Ignacio Matos, Jean‐Pierre Delord, Philippe A. Cassier, Marta Gil-Martín, (unknown), Patricia LoRusso, Rastilav Bahleda, Antoîne Italiano, Diana Mendus, Tien Hoang, (unknown), Xingqiao Wen, (unknown), Thao D. Pham, Namrata S. Patil, (unknown), Johanna C. Bendell, Andrés Cervantes, (unknown)	15
13	824P Real-world-data (RWD) on platinum (Pt) outcomes after PARP inhibitors (PARPi) progression in high grade serous ovarian cancer (HGSOC) patients (p) 2020 ·Annals of Oncology ·(unknown), (unknown), (unknown), Marta Gil-Martín, Josep M. Piulats, (unknown), M.P. Barretina Ginesta, (unknown), (unknown), (unknown), (unknown), Aurélie Gomez, Mar Marín	3
14	Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study 2019 ·Breast Cancer Research and Treatment ·Alberto Ocaña, Marta Gil-Martín, Silvia Antolín, (unknown), Álvaro Montaño, Nuria Ribelles, Ander Urruticoechea, Alejandro Falcón, Sònia Pernas, (unknown), Juan Carlos Montero, M.J. Escudero, Sara Benito, Rosalía Caballero, Eva Carrasco, Federico Rojo, Atanasio Pandiella, Manuel Ruíz‐Borrego	36
15	Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study breakdown → 2018 ·Journal of Clinical Oncology ·Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Jankú, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiss‐Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga	302
16	A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients 2018 ·Human Gene Therapy ·Margarita García, Rafael Moreno, Marta Gil-Martín, Manel Cascalló, María Ochoa de Olza, (unknown), Josep M. Piulats, Valentín Navarro, Marta Doménech, Ramón Alemany, Ramón Salazar	80
17	A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04 2017 ·Annals of Oncology ·(unknown), Manuel Ruíz Borrego, Marta Gil-Martín, Silvia Antolín, (unknown), Alfredo Montaño, Nuria Ribelles, (unknown), Montserrat Muñoz-Mateu, (unknown), Ander Urruticoechea, Alejandro Falcón, Sònia Pernas, (unknown), M.J. Escudero, Sara Benito, Rosalía Caballero, Eva Carrasco, Federico Rojo, Atanasio Pandiella	1
18	CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study 2017 ·Annals of Oncology ·John D. Powderly, Manish R. Patel, Jina Lee, Joshua Brody, Funda Meric‐Bernstam, Erika Hamilton, Santiago Ponce Aix, Javier García-Corbacho, Y-J. Bang, M-J. Ahn, Sun Young Rha, Kwang Pyo Kim, Marta Gil-Martín, (unknown), Adam S. Lazorchak, Timothy Wyant, Anna Ma, Shefali Agarwal, David Tuck, Adil Daud	45
19	Phase III study of Ribociclib (LEE011) in combination with Fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have received no or only one line of prior endocrine treatment : MONALEESA-3 2016 ·Clinical Cancer Research ·PA Fasching, Guy Jérusalem, Xavier Pivot, Marta Gil-Martín, Michelino De Laurentiis, K. L. Blackwell, Francisco J. Esteva, (unknown), Zhenrong Tang, Karen Rodriguez Lorenc, Dennis J. Slamon	3
20	Complete and Sustained Objective Response per RECIST to Irvalec (PM02734) in Undifferentiated Large Cell Esophageal Adenocarcinoma: A Case Report and a Review of the Literature 2012 ·Case Reports in Oncology ·Ramón Salazar, (unknown), Marta Gil-Martín, (unknown), Vicente Alfaro, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact